La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Actinium Pharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Actinium Pharma..

Actinium Pharma (AMEX:ATNM) Azioni, Catena delle Opzioni

ACTINIUM PHARMACEUTICALS INC

Actinium Pharmaceuticals

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGRI

ATNM

ATPC

BJDX

CHGG

CNSP

HPAI

LCID

LUMN

PLTR

RXST

SERV

SMFG

SPWR

TENK

TPET

UPXI

Pre-market: Palantir guida i rialzi con un +9,6%, mentre SunPower e Chegg mostrano cali significativi. Scopri i dettagli.

Chi sale e chi scende: i maggiori movimenti nel pre-market di oggi

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharmaceuticals Inc

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) with a Buy and maintains $4 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $4 Price Target

-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Iomab-ACT supported by results of NIH funded trial with MSK showing effective lymphodepletion of targeted immune cells resulting in negligible rates of CAR-T toxicities ICANS and CRS and CAR T-cell persistence with a novel CD19 CAR-T therapy
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Iomab-ACT has the potential to increase the addressable market for CAR-T therapies, which generated $4 billion in sales in 2024, by enabling improved access and better patient outcomes compared to current chemotherapy conditioning agents
NEW YORK, May 6, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first patient was enrolled on the trial studying Iomab-ACT targeted conditioning with a commercial CAR-T therapy at the University of Texas Southwestern Medical Center (UTSW) (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4420488-1&amp;h=3859462182&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06768905%3Fintr%3DIomab-ACT%26rank%3D1&amp;a=NCT06768905">NCT06768905</a>). Initial clinical data from this trial is expected in the second half of 2025. Actinium is developing Iomab-ACT as a targeted radiotherapy conditioning agent intended to replace non-targeted chemotherapeutic conditioning agents such as Fludarabine and Cyclophosphamide (Flu/Cy) to address serious CAR-T related toxicities including immune effector cell-associated neurotoxicity (ICANS) and cytokine release syndrome (CRS), to potentially improve patient access and outcomes. Currently, there are seven CAR-T therapies approved for certain leukemias and lymphomas and multiple myeloma, that over 150,000 patients are diagnosed with annually. &nbsp;In 2024, the seven approved CAR-T therapies generated over $4 billion in sales and CAR-T therapies are forecasted to reach $12 billion in annual sales in 2030.

Biotech

General

Actinium Announces Enrollment Of First Patient In The Iomab-ACT Commercial CAR-T Trial At The University Of Texas Southwestern Medical Center; Initial Clinical Data Expected In The Second Half Of 2025

-&nbsp; Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists following Pluvicto therapy and ATNM-400 demonstrates sustained tumor control after Pluvicto stops working
-&nbsp; ATNM-400 showed greater tumor growth inhibition compared to Pluvicto in prostate cancer models with 99.8% tumor growth inhibition achieved with a single 40 µCi/kg dose of ATNM-400 demonstrating the potential to be offered as an alternative option
-&nbsp; ATNM-400 was well tolerated with no apparent toxicities at two different dose levels, with efficient clearance from essential organs
NEW YORK, April 28, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced preclinical results with ATNM-400 in prostate cancer models presented at the American Association for Cancer Research (AACR) Annual Meeting. ATNM-400 is a novel, non-PSMA targeting, first in class targeted radiotherapy utilizing the Actinium-225 (Ac-225) radioisotope that Actinium is evaluating in prostate cancer models prior to and following treatment with Pluvicto. Pluvicto (Lu-177-PSMA-617) is a prostate-specific membrane antigen (PSMA) directed radiotherapy radiolabeled with the beta-particle emitter, Lutetitium-177 (Lu-177) is approved for patients with metastatic castration-resistant prostate cancer. Pluvicto is marketed and sold by Novartis and generated sales of $1.39 billion in 2024.

Actinium Pharma Announces ATNM-400 Preclinical Data Highlighting Sustained Tumor Control and Safety for Prostate Cancer Patients Post-Pluvicto

<ul>
<li>Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML models</li>
<li>Actimab-A is the only CD33 targeted radiotherapy with Actinium-225 isotope payload in development for AML and other myeloid malignancies
<ul>
<li>Actimab-A is currently being advanced in several combination studies including a Phase 2/3 trial in combination with CLAG-M in relapsed/refractory AML and in combination with Venetoclax and ASTX-727, an oral hypomethylating agent from Taiho Oncology in frontline AML under a CRADA with the NCI</li>
</ul>
</li>
</ul>

Events

Actinium Highlights Mutation Agnostic Antileukemic Activity Of Actimab-A Against FLT3, NPM1, KMT2A And TP53 Mutations in AML Models Demonstrating Backbone Potential For Acute Myeloid Leukemia Treatment

The update featured the unveiling of ATNM-400, Actinium's new Actinium-225 (Ac-225) solid tumor program, which is a novel, non-PSMA targeting, first-in-class radiotherapy for prostate cancer. Initial preclinical data from ATNM-400 will be presented at AACR on April 27, 2025.

Actinium Provides Business Update Detailing Recent Achievements And Anticipated Milestones From Its Clinical Pipeline

<h3>Gainers</h3>
<ul>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares rose 246.0% to $0.2 during Wednesday's regular session. The market value of their outstanding shares is at $5.0 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) shares increased by 112.49% to $3.4. The market value of their outstanding shares is at $65.5 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock increased by 92.07% to $0.11. The company's market cap stands at $15.3 million. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock increased by 46.09% to $0.99. The market value of their outstanding shares is at $3.8 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) stock increased by 21.36% to $0.11. The market value of their outstanding shares is at $1.8 million. </li>
<li>Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) stock increased by 20.56% to $1.91. The company's market cap stands at $59.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) stock fell 39.1% to $3.28 during Wednesday's regular session. The market value of their outstanding shares is at $102.1 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) stock fell 29.92% to $2.02. The market value of their outstanding shares is at $259.2 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares decreased by 28.27% to $2.69. The market value of their outstanding shares is at $8.4 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock declined by 21.02% to $0.59. The company's market cap stands at $8.0 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock declined by 17.63% to $7.29. The market value of their outstanding shares is at $63.4 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares decreased by 16.87% to $0.66. The company's market cap stands at $47.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

ACRV

CRVO

CTOR

HUMA

OCEA

OSRH

PTPI

TNON

12 Health Care Stocks Moving In Wednesday's Intraday Session

WIIM

Actinium Pharmaceuticals shares are trading higher after the company announced it is going to present a business update at Trump Mar-a-Lago Club.

- Company to highlight recent significant progress made with its&nbsp;Actimab-A and Iomab-ACT clinical programs, leading-edge R&amp;D and radiopharmaceutical manufacturing infrastructure
- Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in myeloid malignancies, solid tumors and cell &amp; gene therapy conditioning with clinical data expected in 2025 supporting each addressable market
- Presentation follows Investor KOL Event and Company Update on March 25th
NEW YORK, March 26, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, announced it will be presenting a business update today at Trump Mar-a-Lago Club, Florida. This presentation follows an Investor KOL Call and Company Update hosted by Actinium on Tuesday, March 25th highlighting its revitalized clinical programs and expanded market opportunities. Actinium's Investor KOL Call and Company Update can be accessed for replay <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4391613-1&amp;h=2186212444&amp;u=https%3A%2F%2Flifescievents.com%2Fevent%2Factinium-2%2F&amp;a=here">here</a>. &nbsp;

Actinium Pharmaceuticals To Present Business Update At Trump Mar-A-Lago Club Today; Revitalized Clinical Programs Focused On 3 Separate Market Opportunities In Myeloid Malignancies, Solid Tumors And Cell & Gene Therapy Conditioning With Clinical Data Expected In 2025

Actinium Pharmaceuticals, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a pioneer in the development of targeted radiotherapies,&nbsp;today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert &amp; Ziegler. Under this agreement, Actinium Pharmaceuticals will have access to Eckert &amp; Ziegler's high-quality Actinium-225 to further develop its lead product Actimab-A as well as additional early and late-stage development candidates for both U.S. and international clinical trials.
&nbsp;
Targeted radiotherapies using Ac-225 have shown great promise in the treatment of cancer. The radioisotope releases powerful alpha particles with high energy and low penetration depth, enabling precise targeting of tumor cells, including hard-to-reach micrometastases, while minimizing effects on surrounding healthy tissue. Actimab-A is an Ac-225 based radiotherapy agent, directed against CD33, a receptor overexpressed in patients with acute myeloid leukemia (AML) and other myeloid indications.

Actinium Pharmaceuticals Enters Agreement With Eckert & Ziegler For Supply Of Actinium-225 To Develop Actimab-A And Other Candidates For U.S. And International Trials; Terms Not Disclose

Actinium Pharmaceuticals shares are trading higher after the company announced it entered a research collaboration with Memorial Sloan Kettering for clinical expansion of Actimab-A's backbone therapy strategy.

Contracts

Actinium Pharmaceuticals To Collaborate With Memorial Sloan Kettering For Clinical Expansion Of Actimab-A's Backbone Therapy Strategy

Actinium Pharmaceuticals Announces A Clinical Trial Program For Solid Tumors Combining Actimab-A With PD-1 Checkpoint Inhibitors KEYTRUDA And OPDIVO; Clinical Proof Of Concept Data Expected In 2025

-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mutation agnostic potential of Actimab-A demonstrated by high rates of Complete Remissions and Measurable Residual Disease Negativity in patients with high-risk features including TP53 mutations and prior Venetoclax treatment
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Actimab-A + CLAG-M combination yielded deep and clinically meaningful responses with expected and manageable safety profile supporting planned pivotal Phase 2/3 trial
NEW YORK, March 17, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M in patients with relapsed/refractory acute myeloid leukemia (r/r AML) have been published in the peer-reviewed journal Leukemia. The publication highlights data including long-term survival outcomes from two-year follow-up and better outcomes in high-risk patients. Actimab-A is a novel targeted radiotherapeutic that uses the Actinium-225 (Ac-225) isotope payload directed against CD33, a marker expressed ubiquitously on AML blasts. The trial was conducted at the Medical College of Wisconsin (MCW) which has extensive experience treating relapsed refractory AML patients with CLAG-M.
Actimab-A + CLAG-M Trial Data Highlights from Publication:
<ul>
<li>18.4 month median Overall Survival (OS) in patients who received 1 or 2 lines of prior therapy</li>
<li>52% of patients in the Actimab-A +CLAG-M trial had TP53 mutations, 56% had prior allogeneic stem cell transplant and 56% of patients had prior Venetoclax therapy</li>
<li>Actimab-A + CLAG-M outcomes compare favorably to the results from historical data with CLAG-M alone in the pre-Venetoclax era from MCW's study (median OS of 13.3 months). Typically, patients who have failed Venetoclax treatment demonstrate median survival between 2.4 – 4.6 months as reported in the literature and the patients with a TP53 mutation even have more dismal survival outcomes. Hence this data supports the use of Actimab-A plus CLAG-M for these patients.</li>
<li>Actimab-A + CLAG-M produced high rates of measurable residual disease negativity (MRD-) including 75% across all patients, 83.3% in patients with a TP53 mutation and 100% in patients with prior Venetoclax therapy</li>
<li>71% of eligible patients received a bone marrow transplant (BMT) and median OS in these patients was 24.05 months</li>
</ul>

Actinium Pharmaceuticals Announces Publication Of Actimab-A + CLAG-M Trial Results In Patients With Relapsed Or Refractory Acute Myeloid Leukemia In The Peer-Reviewed Journal Leukemia

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM

Legal

ATNM INVESTOR ALERT: Kirby McInerney LLP Reminds Actinium Pharmaceuticals, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit

ATNM Deadline: ATNM Investors with Losses in Excess of $100K Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Ultra Clean, and SoundHound and Encourages Investors to Contact the Firm

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Shareholders that lost money on Actinium Pharmaceuticals, Inc. (ATNM) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

ATNM DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action – ATNM

Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact Levi & Korsinsky

ATNM Deadline: Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

SOUN

UCTT

Adicet Bio

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Actinium Pharma

bluebird bio

Biomea Fusion

Celularity

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Fortress Biotech

Forte Biosciences

Gain Therapeutics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

ImmuCell

Immuneering Corporation - Class A Common Stock

Immuneering

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Opus Genetics

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

MAIA Biotechnology

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Quince Therapeutics

Renovaro

Repare Therapeutics

Serina Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

HC Wainwright & Co.

Stephens & Co.

Maxim Group

Cantor Fitzgerald

B. Riley Securities

Screenshot 2024-02-29 at 7.16.11 PM

COEP

Here&#39;s How Coeptis Therapeutics Is Innovating Cell Therapy Approaches

Comments

Actinium Pharma

Actinium Pharma (ATNM) Opzioni

Actinium Pharma (AMEX:ATNM) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO